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Abstract 15 
Study Question: In women undergoing IVF/ICSI who miscarry in their first complete cycle, what is the 16 
chance of a live birth in subsequent complete cycles, and how does this compare with those whose 17 
first complete cycle ends with live birth or without a pregnancy? 18 
Summary Answer: After two further complete cycles of IVF/ICSI, women who had miscarried or had 19 
a live birth in their first complete cycle had a higher chance of live birth (40.9% and 49.0% respectively) 20 
than those who had no pregnancies (30.1%). 21 
What is known already: Cumulative live birth rates after one or more complete cycles of IVF have 22 
been reported previously, as have some of the risk factors associated with miscarriage, both in general 23 
populations and in those undergoing IVF. Chances of cumulative live birth after a number of complete 24 
IVF cycles involving replacement of fresh followed by frozen embryos after an initial miscarriage in a 25 
population undergoing IVF treatment have not been reported previously. 26 
Study design, size and duration: National population-based cohort study of 112549 women who 27 
started their first IVF treatment between 1999 and 2008. 28 
Participants/materials, setting, methods: Data from the United Kingdom Human Fertilisation and 29 
Embryology Authority (HFEA) register on IVF/ICSI treatments, using autologous gametes were 30 
analysed. Cumulative live birth rates (CLBRs) were estimated in women who a) had miscarriage (and 31 
no live birth), b) at least one live birth or c) no pregnancy in their first complete cycle of IVF/ICSI 32 
(including fresh and frozen embryo transfers following a single oocyte retrieval episode). A 33 
multivariable analysis was performed to assess the effect of first complete cycle outcome on 34 
subsequent CLBRs after adjusting for confounding factors such as female age, duration of infertility 35 
and cause of infertility.  36 
Main results and the role of chance: In their first complete cycle, 9,321 (8.3%) women had at least 37 
one miscarriage (and no live birth); 33,152 (29.5%) had at least one live birth and 70,076 (62.3%) had 38 
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no pregnancies. After two further complete cycles, conservative CLBRs (which assume that women 39 
who discontinued treatment subsequently never had a live birth) were 40.9%, 49.0% and 30.1% , while 40 
optimal CLBRs (which assume that women who discontinue have the same chance of live birth as 41 
those treated) were 49.5%, 57.9% and 38.4% in the miscarriage, live birth and no pregnancy groups 42 
respectively. Odds of cumulative live birth for women who miscarried in their first complete cycle 43 
were 42% higher than those who had no pregnancy [odds ratio (95% confidence interval) = 1.42 (1.34, 44 
1.50)], and twice as high for live birth versus no pregnancy [2.04 (1.89, 2.20)]. Negative predictors for 45 
live birth in all women included tubal infertility [0.88 (0.82, 0.94)] and increasing age [18-40 years=0.94 46 
(0.94, 0.95); >40 years=0.63 (0.59, 0.66)].   47 
Limitations and reason for caution: CLBRs could not be estimated for treatments occurring after 48 
September 2008 due to potentially incomplete data following regulatory changes regarding consent 49 
for data use in research. Additionally, covariates not included in the HFEA database (including body 50 
mass index, smoking, previous history of miscarriage and gestational age at miscarriage) could not be 51 
adjusted for in our analysis. 52 
Wider implications of the findings: Miscarriage following IVF can be devastating for couples who are 53 
uncertain about their ultimate prognosis. Our findings will provide reassurance to these couples as 54 
they consider their options for continuing treatment.  55 
Study funding/competing interest(s): N.J.C. received an Aberdeen Summer Research Scholarship 56 
funded by the Institute of Applied Health Sciences (University of Aberdeen), through the Aberdeen 57 
Clinical Academic Training Scheme. This work was supported by a Chief Scientist Office Postdoctoral 58 
Training Fellowship in Health Services Research and Health of the Public Research (Ref PDF/12/06). 59 
The views expressed here are those of the authors and not necessarily those of the Chief Scientist 60 
Office or the University of Aberdeen. The funders did not have any role in the study design; in the 61 
collection, analysis and interpretation of data; in the writing of the report; nor in the decision to submit 62 
the paper for publication. None of the authors has any conflicts of interest to declare. 63 
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Introduction 66 
 67 
IVF is the treatment of choice for couples with prolonged unresolved infertility (National Collaborating 68 
Centre for Women’s and Children’s Health 2013). A total of 52,288 women underwent 67,708 cycles 69 
of IVF or ICSI in the UK in 2014 and 1.5% of all babies born in the UK each year are conceived using IVF 70 
or ICSI (Human Fertilisation and Embryology Authority 2012). Although 26.5% of IVF treatments in the 71 
UK result in a live birth (Human Fertilisation and Embryology Authority 2016) 22.3% of IVF pregnancies 72 
end in miscarriage (Sunkara et al. 2014). 73 
A miscarriage can be a devastating experience for any individual (Toffol et al. 2013) but especially so 74 
for women who conceive through ART (Cheung et al. 2013, Toffol et al. 2013). This prompts some 75 
patients to discontinue further treatment due to fears about the emotional burden associated with 76 
repeated failed cycles of IVF (Harris and Daniluk 2010). Patients who continue with treatment 77 
following a previous miscarriage have described high levels of anxiety affecting their decision to invest 78 
in future treatments and pregnancies due to the uncertainty of the process and the fear of another 79 
pregnancy loss (Freda et al. 2003, Harris and Daniluk 2010).  80 
Previous work has identified some of the risk factors associated with miscarriage including increasing 81 
maternal age (Baker et al. 2010, Croucher et al. 1998, Hipp et al. 2016), previous miscarriages and 82 
polycystic ovary syndrome (Joham et al. 2014, Knudsen et al. 1991, Kupka et al. 2004, Rai and Regan 83 
2006). IVF-specific risk factors include the transfer of cryopreserved embryos, cleavage-stage embryo 84 
transfer, decreased response to ovarian stimulation (linked to maternal age), previous miscarriages in 85 
IVF conceptions and certain causes of infertility such as uterine factor and endometriosis (Croucher et 86 
al. 1998, Hipp et al. 2016, Kupka et al. 2004, Yang et al. 2015). 87 
Of the existing studies on miscarriage following IVF, only a handful have reported on the effect of a 88 
previous miscarriage on subsequent success rates (Croucher et al. 1998, Kalu et al. 2011, Kupka et al. 89 
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2004, Yang et al. 2015). Both Kupka et al., (2004) and Yang et al., (2015) reported overall IVF related 90 
clinical pregnancy rates and miscarriage rates following miscarriage. Kupka et al., (2004) reported 91 
these following any history of previous miscarriage, while Yang et al., (2015) studied success rates 92 
after miscarriage in the first embryo transfer. However, they did not compare cumulative live birth 93 
rates of those who had a miscarriage with those who had a live birth or those who did not get pregnant 94 
over multiple cycles, therefore not reflecting the ongoing, cyclical nature of IVF treatment. Although 95 
cumulative live birth rates have been acknowledged as the optimum way of expressing outcomes after 96 
a course of IVF treatment, this is the first to examine the effect of previous miscarriage on cumulative 97 
live birth rates (CLBRs), while adjusting for confounders in terms of patient and treatment 98 
characteristics. 99 
The Human Fertilisation and Embryology Authority collects IVF treatment data from all licenced UK 100 
treatment centres.  An anonymised version of this database can be freely used in research (Human 101 
Fertilisation and Embryology Authority 2013). However, these individual fresh or frozen treatments 102 
are not linked to complete cycles (defined as all fresh and frozen-thawed embryo transfer attempts 103 
resulting from one episode of ovarian stimulation) (Moragianni and Penzias 2010) or to individual 104 
women, and so do not allow for calculation of CLBRs. Where strict ethical requirements are met, the 105 
HFEA allows access to a more detailed version of this database which does link treatments to women, 106 
providing the opportunity to estimate CLBRs per woman and, thus, the total reproductive potential of 107 
each cycle (McLernon et al. 2016, McLernon et al. 2016). 108 
In women who had i) a miscarriage (and no live birth); ii) no pregnancy; or iii) a live birth, by the end 109 
of their first complete IVF cycle (i.e. fresh followed by frozen replacement cycles after an initial episode 110 
of oocyte retrieval) we estimated the cumulative live birth rates following subsequent complete cycles 111 
of IVF. We estimated the chance of a live birth over subsequent complete cycles in each of the three 112 
groups of women after adjusting for other patient and treatment characteristics.  113 
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Materials and methods 114 
Database access  115 
 Access to the more detailed version of the HFEA database was granted following approval from the 116 
HFEA Register Research Panel, the North of Scotland Research Ethics Committee and the 117 
Confidentiality Advisory Group. The data were anonymised and transferred to the University of 118 
Aberdeen where they were stored on the Data Safe Haven (DaSH) server for analysis. Access to this 119 
dedicated secure server was limited to the authors. 120 
Ethical approval  121 
The North of Scotland Research Ethics Committee granted ethical approval (12/NS/0119). 122 
Study population  123 
Records on all women who initiated their first complete IVF cycle in the UK at a licenced clinic from 124 
January 1999 to September 2008 with frozen embryo transfers continuing until September 2009 were 125 
extracted. Complete cycles were combined on a per-woman basis and were defined as all fresh and 126 
frozen-thawed embryo transfers associated with one episode of ovarian stimulation (Moragianni and 127 
Penzias 2010). This allowed estimation of the total reproductive potential of each complete cycle, as 128 
well as the calculation of CLBRs. 129 
 130 
The following exclusion criteria were applied (see Figure 1): 131 
(i) Women older than 50 years, or less than 18 years, at the time of their first treatment. 132 
(ii) Women whose treatment involved surrogacy or use of donor eggs or sperm. 133 
  
 
8 
(iii) Women whose treatment was for the purpose of egg/embryo storage only. 134 
(iv) Women who appeared to have previous unrecorded treatments (i.e. frozen-thawed embryo 135 
transfer listed as their first treatment). 136 
(v) Women whose first fresh embryo transfer attempt occurred after 30th September 2008. 137 
(vi) Women whose treatments, as recorded in the database, lacked important data such as outcome 138 
of first cycle, diagnosis type, etc.  139 
(vii) Women with a diagnosis of cervical infertility. 140 
(viii) Women who were lost to follow up during their first cycle and so had no recorded outcome. 141 
(ix) Women with first complete cycle outcomes other than miscarriage, live birth or no pregnancy (i.e. 142 
termination, ectopic pregnancy, molar pregnancy, stillbirth, embryo reduction). 143 
(x) Treatments occurring after 30th September 2009 were excluded because after this date the policy 144 
for giving consent for identifying IVF patient data to be used in research changed from assumed (opt-145 
out) to required (opt-in). This meant that including treatments from further years would have led to 146 
inaccurate discontinuation rates in analysis if women chose not to give consent for the use of their 147 
treatment information after this point. 148 
Baseline characteristics  149 
We considered the following characteristics for women at the start of their first treatment: year; 150 
duration of infertility (years); type of infertility (unexplained, endometriosis, tubal, anovulatory, or 151 
multiple diagnoses); and age. Treatment characteristics were also assessed, including: type of 152 
treatment used (IVF/ICSI); number of oocytes collected; number of embryos transferred; number of 153 
complete cycles undertaken; number of complete cycles until live birth and time (days) from first 154 
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treatment to the treatment that led to live birth. Descriptive numbers of other causes of pregnancy 155 
loss were also recorded but for the purposes of the research question, we focussed on miscarriage 156 
(including biochemical pregnancy).  157 
Exposure groups 158 
Participants were stratified into three cohorts depending on the best outcome of first complete cycle 159 
of treatment: any live birth, miscarriage (and no live birth), and no pregnancy. Women whose outcome 160 
did not fall into these categories (e.g. ectopic pregnancy, termination, stillbirth, embryo reduction) 161 
were not included in analysis due to relatively small numbers. 162 
Outcomes   163 
The main outcomes were cumulative live birth rate per woman from the second complete cycle 164 
onwards.  165 
In women who had a live birth resulting from IVF treatment in their first complete cycle, and continued 166 
with treatment, the cumulative live birth rate was calculated for the occurrence of their second live 167 
birth.  All complete cycles contributed to the CLBR up until the complete cycle in which a second live 168 
birth occurred or until their last unsuccessful complete cycle. 169 
For women who did not have a live birth in their first complete cycle (i.e. experienced a miscarriage 170 
or did not get pregnant), and continued with treatment, the cumulative live birth rate for the 171 
occurrence of their first live birth was calculated.  Women who achieved a first live birth from IVF no 172 
longer contributed to the cumulative live birth rate. 173 
Statistical Analysis 174 
Descriptive statistics of the first and second complete cycle patient and treatment characteristics were 175 
generated both for each cohort. Patient-level characteristics studied were the mean (SD) of age; 176 
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median (interquartile range (IQR)) of duration of infertility; the frequency and percentage of primary 177 
versus secondary infertility and of each type of infertility (more than one cause, tubal, anovulatory, 178 
male factor, endometriosis, and unexplained). Treatment-level characteristics collected for both first 179 
and second complete cycles included frequency and percentage of IVF and ICSI treatments; the 180 
median (IQR) number of eggs retrieved; frequency and percentage of the number of embryos 181 
transferred and the stage at which they were transferred (no transfer, single cleavage, single 182 
blastocyst, double cleavage, double blastocyst, triple cleavage, triple blastocyst). For the first 183 
complete cycle alone the following additional characteristics were studied: frequency and percentage 184 
of live births; median (IQR) number of complete cycles until live birth and median (IQR) time (days) 185 
from first treatment until last treatment before live birth.  The descriptive statistics of patients at the 186 
first complete cycle are shown in Supplementary Table I, and treatment information in Supplementary 187 
Table II. 188 
Additionally, the outcomes of the second complete cycle were analysed for each cohort and broken 189 
down into the following categories: no pregnancy, live birth (and no pregnancy loss), miscarriage (and 190 
no live birth), miscarriage (and live birth), other pregnancy loss, discontinued treatment after first 191 
complete cycle, and lost to follow up. 192 
As well as cumulative live birth rates, conditional live birth rates were estimated from the second 193 
complete cycle onwards for each of the three cohorts (i.e. miscarriage, no pregnancy, live birth). Three 194 
different live birth rates were calculated for each of the three cohorts: 195 
Live birth rate per complete cycle (conditional live birth rate) 196 
This was calculated by dividing the number of women who had their first live birth (with exception of 197 
women from the live birth cohort for whom it was second live birth) in each complete cycle by the 198 
number of women who attempted that complete cycle. 95% confidence intervals were calculated 199 
using the standard errors from the binomial distribution. 200 
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Conservative cumulative live birth rate 201 
This method assumes that women who discontinued treatment would never have a live birth. At each 202 
complete cycle the number of women who had a live birth from complete cycle two until that 203 
complete cycle inclusive was divided by the number of women who continued treatment into 204 
complete cycle two.  205 
Complete cycles occurring after the complete cycle which resulted in a first live birth were excluded 206 
from the CLBRs. For women who had a live birth in their first complete cycle, complete cycles occurring 207 
after that which resulted in their second live birth were excluded.  Women who did not return for 208 
treatment were also not included in further analyses. The 95% confidence intervals were calculated 209 
as for the conditional live birth rates. 210 
Optimal cumulative live birth rate 211 
Optimal estimates of the CLBR are based on the assumption that women who did not return to 212 
treatment would have the same chance of a live birth as those who did. As for the conservative rates, 213 
women were excluded from further assessment after live birth or discontinuation occurred (Figure 214 
S1). The optimal CLBRs were calculated using Kaplan-Meier estimates, with Greenwood’s formula 215 
used to calculate the standard error for each of these, and 95% confidence intervals estimated from 216 
the standard errors. The log-rank test was used to compare the differences in optimal CLBRs between 217 
each cohort group. 218 
For both conservative and optimal CLBR estimates, if less than 100 women from the cohort being 219 
assessed attempted a complete cycle, it was excluded. 220 
Multivariable analysis 221 
A multivariable logistic regression model was used to assess the effect of each cohort on the 222 
cumulative chances of a live birth from the second complete cycle onwards whilst adjusting for 223 
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confounding factors.  Complete cycle number was included in the model as a categorical covariate (i.e. 224 
each row of data represented a complete cycle per patient) along with the cohort i.e. outcome of first 225 
complete cycle (live birth versus no pregnancy, miscarriage versus no pregnancy). The following 226 
factors as measured at the start of the second complete cycle were included: female age; duration of 227 
infertility; primary versus secondary infertility; time (months) since the last embryo transfer attempt 228 
of complete cycle one; cause of infertility; treatment type (IVF/ICSI); number of oocytes collected and 229 
number and stage of embryos transferred (no transfer, single cleavage, single blastocyst, double 230 
cleavage, double blastocyst, triple cleavage, triple blastocyst).  Female age at second complete cycle 231 
was found to have a non-linear relationship with the probability of live birth and was fitted as two 232 
linear effects. 233 
 234 
The data was analysed using IBM SPSS v23. 235 
Results 236 
After exclusion criteria were applied, 113518 women who entered their first complete cycle between 237 
January 1999 and September 2008 were included. Of these, 112549 were then grouped into 3 cohorts 238 
according to the outcome of their first complete cycle i.e. no pregnancy (n=70076 (62.3%)), live birth 239 
(n=33152 (29.5%)) and miscarriage (n=9321 (8.3%)).  The other outcomes were other forms of 240 
pregnancy loss, including ectopic pregnancy, stillbirth, termination and embryo reduction. Table I 241 
shows causes of pregnancy loss in women who had a pregnancy loss (and no live birth) in their first 242 
complete cycle. Miscarriage and biochemical pregnancy were the two most frequent pregnancy losses 243 
in the first complete cycle (4.2 and 3.9% of the whole population respectively). All other pregnancy 244 
losses were excluded and miscarriage and biochemical pregnancy were grouped into one miscarriage 245 
cohort. The proportion of pregnant women who had a miscarriage anywhere in the first complete 246 
cycle, regardless of live birth, in our population was 25.7%. 247 
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Characteristics of participants 248 
 249 
The mean age (SD) of women at the start of their second complete cycle was similar across all three 250 
cohorts at 35 years (Table II). The median duration of infertility was four years for the miscarriage 251 
cohort, slightly lower than for the no pregnancy and live birth cohorts at 5 and 6 years respectively. 252 
The distribution of infertility diagnoses was similar across all cohorts, with male factor the most 253 
frequent diagnosis, followed closely by unexplained infertility.  254 
Table III presents treatment characteristics of the first fresh transfer of couples’ second complete cycle 255 
by outcome of first complete cycle. Women who had no pregnancies in their first complete cycle had 256 
a lower median (IQR) number of oocytes collected (8 (5-12)) than those who had miscarriage (9 (5-257 
13)) or live birth (10 (6-14)).  Of those women who had no pregnancy in their first complete cycle, 258 
11.7% had no embryos transferred in their first fresh cycle – a 4.9% increase compared to the other 259 
two cohorts in both of which 6.8% had no transfer.  260 
There was missing data for the following characteristics at the start of the second complete cycle: 261 
duration of infertility (5147; 10.6%); cause of infertility (214; 0.4%) and stage and number of embryos 262 
transferred (721; 1.4%). Over all woman assessed, 5953 (12.1%) had missing data in any of the second 263 
complete cycle characteristics. 264 
We assumed that this information was missing at random and used a complete case analysis. 265 
Of women who had a miscarriage in their first complete cycle, 12.1% went on to have another 266 
miscarriage and no live birth in the second complete cycle, and 2.2% had another miscarriage but also 267 
a live birth – both of these were an increase compared to the other two cohorts (Table IV). The 268 
proportion of women who had a live birth and no pregnancy loss in the second complete cycle was 269 
highest in the live birth cohort at 36.6%, compared to 29.3 and 21.5% in the miscarriage and no 270 
pregnancy cohorts respectively. 271 
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Live birth rates 272 
The cumulative live birth rate was calculated for each of the three cohorts over a maximum of six 273 
complete cycles. Miscarriage (and no live birth) in the first complete cycle was associated with an 274 
optimal cumulative live birth rate of 72.4% after a further five complete cycles. All live birth rates 275 
calculated showed a difference between the cohorts. 276 
In subsequent complete cycles, by first complete cycle outcome 277 
The conditional and cumulative live birth rates varied across the three cohorts (Table V). 278 
The conditional live birth rate at the second complete cycle differed between the three cohorts at 279 
22.8% for those who had no pregnancies, 31.7% for miscarriage and 38.8% for those who had a live 280 
birth in their first complete cycle. In each cohort, the conditional live birth rate decreased with each 281 
successive complete cycle.  282 
An outcome of miscarriage in the first complete cycle was associated with a higher conservative 283 
(44.0%) and optimal (67.1%) CLBR at complete cycle five compared to no pregnancy (33.1 and 57.8% 284 
respectively) (see Figure 2). However, an outcome of live birth in the first complete cycle was 285 
associated with the highest cumulative live birth rates: at complete cycle five, the conservative and 286 
optimal estimates were 52.6 and 75.5%. The difference in optimal CLBRs between the three cohorts 287 
was highly significant (p <0.001).  288 
Age group 289 
Figure 3 illustrates optimal cumulative live birth rates in each cohort group stratified by age group at 290 
first complete cycle. Across all cohort groups, optimal cumulative live birth rates decreased in older 291 
age groups.  292 
 293 
Multivariable analysis 294 
The results of the final model are represented in Table VI.  295 
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Women who had either a miscarriage or a live birth over the first complete cycle of IVF had a higher 296 
chance of live birth over subsequent complete cycles compared to women who never had a pregnancy 297 
in their first complete cycle.  Women who miscarried in their first complete cycle had 42% increased 298 
odds of live birth compared to women who had no pregnancy [adjusted odds ratio (95% confidence 299 
interval) =1.42 (1.34, 1.50)]. Those who had a live birth in their first complete cycle also had improved 300 
chances of live birth: their odds were twice those of women who had no pregnancy [2.04 (1.89, 2.20)].  301 
 302 
When compared to the second complete cycle, chances of live birth decreased with each successive 303 
cycle. Increasing female age at the second complete cycle was associated with decreased odds of live 304 
birth, especially over the age of 40 years [18-40 years = 0.94 (0.94, 0.95); >40 years=0.63 (0.59, 0.66)].  305 
Over 40 years the odds of a live birth decreased by 37% with every increasing year of age.  Increasing 306 
duration of infertility was associated with lower chances of a live birth [0.99 (0.98, 0.99)]. A diagnosis 307 
of tubal infertility at the second complete cycle was the only diagnostic group which significantly 308 
reduced the chances of live birth [0.88 (0.82, 0.94)].  309 
Not having a previous live birth (primary infertility) and time between first and second complete cycles 310 
were not significantly associated with cumulative live birth and were excluded from the model.  311 
Year of second complete cycle, which accounted for changes in practice and treatment with time, was 312 
positively associated with live birth [1.03 (1.02, 1.04)].  Additionally, the chances of a live birth 313 
increased by 11% when IVF was used rather than ICSI [1.11 (1.05, 1.16)]. The chance of live birth 314 
increased with increasing numbers of eggs collected at the second complete cycle [1.04 (1.04, 1.04) 315 
per egg]. 316 
Compared with double cleavage stage embryo transfers, single, double and triple blastocyst transfers 317 
were all associated with an increased chance of live birth. The transfer of a single cleavage stage 318 
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embryo had half the chances of a live birth compared to the transfer of two cleavage stage embryos 319 
[0.49 (0.45, 0.54)]. 320 
Discussion 321 
Principal findings 322 
We have reported the chances of cumulative live birth following miscarriage in the first complete IVF 323 
cycle, and compared the odds of future live birth to women whose first complete cycle outcome was 324 
either no pregnancy or live birth.  325 
The chances of subsequent live birth increased in a dose dependent manner from no pregnancy to 326 
miscarriage to live birth in the first complete cycle. Although both pregnancy loss and non-pregnancy 327 
are viewed as a ‘failure’, our results show that the two have very different prognoses. 328 
Strengths & weaknesses 329 
This study estimated the cumulative chance of live birth following miscarriage in an IVF population, 330 
and successfully adjusted for known individual patient and treatment predictors of success in IVF using 331 
a multivariable model. Previous studies have reported chance of live birth in IVF after miscarriage, but 332 
did not report CLBRs. Some reported the results of one subsequent cycle rather than CLBRs over 333 
multiple subsequent cycles (Croucher et al. 1998, Kalu et al. 2011, Yang et al. 2015), while others 334 
reported live birth rate per oocyte retrieval, but could not report cumulative rates as there was no 335 
connection between woman and cycle  (Kupka et al. 2004). CLBRs report success over complete cycles 336 
of continued treatment more accurately than single cycle live birth rates, and are seen as a better 337 
measure for counselling couples on chances of success in future cycles (Stern et al. 2010).  338 
One previous study did report cumulative success rates after initial miscarriage, however the authors 339 
chose to use clinical pregnancy rates rather than live birth rates (Bates Jr and Ginsburg 2002). For 340 
women who have experienced miscarriage and are concerned about future pregnancy loss, a CLBR is 341 
  
 
17 
a more clinically relevant measure than a pregnancy rate alone. Additionally, this study did not adjust 342 
for confounding factors using a multivariable model (Bates Jr and Ginsburg 2002). 343 
One limitation of our study is that women who started their first IVF treatment after September 2008 344 
were not included in the analysis. This was due to the risk of incomplete data after changes to 345 
regulations regarding consent for data use in research. If women chose not to disclose their 346 
information for complete cycles occurring after this date our analysis would have returned a higher 347 
discontinuation rate not representative of the population resulting in underestimated cumulative live 348 
birth rates. The lack of the most recent data means that our data may not reflect current practice, for 349 
example: higher frequency of single blastocyst transfers and frozen embryo transfers. 350 
The estimates for CLBRs contain certain assumptions: the optimal estimate assumes that women who 351 
discontinue treatment have a similar chance of live birth as those who continue, while the 352 
conservative estimate assumes the opposite: that those who discontinue have no chance of live birth. 353 
Neither option presents a perfect estimate, as the reasons women leave treatment are likely to be 354 
highly variable and not reported in the HFEA database. By taking into account the available potential 355 
confounders (e.g. type of infertility and age) with the multivariable model, we have adjusted for 356 
treatment continuation based on the available covariates (such as female age). 357 
Due to the retrospective nature of this study, our analysis was limited to predictors included in the 358 
HFEA database. For example, the HFEA database does not contain information on body mass index, 359 
smoking, alcohol intake, ovarian reserve or embryo quality. We were unable to assess the contribution 360 
of diminished ovarian reserve (which is strongly associated with increasing age) separately from 361 
polycystic ovary syndrome (PCOS), as they were not differentiated into different variables in the HFEA 362 
database and no separate measures such as antral follicle count were included in the database. One 363 
important variable that was not available in the HFEA database was previous miscarriage status. 364 
However, we were able to select only women with primary infertility and repeat our analysis. There 365 
was no significant difference in either the CLBRs or results of the multivariable analysis. 366 
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Comparison with existing literature 367 
Our findings are consistent with previous work on IVF outcomes after miscarriage (Bates Jr and 368 
Ginsburg 2002, Croucher et al. 1998, Kalu et al. 2011), and support the verdict that women who have 369 
achieved pregnancy (whether that pregnancy resulted in live birth or miscarriage) in a previous cycle 370 
have a better chance of subsequent live birth than those who did not become pregnant.  371 
However, while Kalu et al. found that any difference between the outcome cohorts lost significance in 372 
women >40 years (Kalu et al. 2011), in our sample it remained significant in all age groups. This could 373 
be due to the much larger sample size in our dataset: Kalu et al. had 348 women in their >40 age 374 
group, while our dataset had 9,019. Additionally, only the second cycle and no frozen transfers were 375 
included, meaning that reproductive potential was not assessed as fully as with the cumulative live 376 
birth rates used in this study.  377 
Early pregnancy loss is often due to chromosomal anomalies in the embryo, which become more 378 
common with increasing maternal age (van den Berg et al. 2012). Pregnancy loss due to chromosomal 379 
anomalies associated with increased maternal age is unrelated to the efficacy of fertility treatment, 380 
as pregnancy has been achieved. However, for women who have no pregnancies, treatment has 381 
‘failed’, perhaps due to unfavourable uterine environment or other causes of infertility, or lesser 382 
response to ovulation induction. This could contribute to the increased live birth rate in women who 383 
experience miscarriage in their initial complete cycle compared to those who have no pregnancies. 384 
Of the causes of infertility assessed, only tubal infertility was a significant, negative, indicator for live 385 
birth. One previous study using the HFEA database found a similar effect (McLernon et al. 2016a), and 386 
suggested it may be due to the effects of treatment variables dominating the impact of the different 387 
diagnoses, particularly for anovulatory, male factor only or unexplained infertility where mild 388 
infertility may be more prevalent.    It could be that infertility diagnosis has a smaller effect on chance 389 
of live birth in those who have previously been able to achieve pregnancy with treatment than those 390 
who have not. Compared to women who have previously achieved pregnancy, women who have not 391 
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become pregnant could have a more fundamental barrier to pregnancy related to implantation of the 392 
embryo or a lower number of eggs available, perhaps making diagnosis a more influential negative 393 
predictor for these women and lowering their chance of live birth. 394 
Interactions between immunogenetic mechanisms and human reproduction have been documented 395 
in normal pregnancy. It has been suggested that expression, regulation and interactions of factors 396 
such as HLA expression, cytokine activity, and natural killer cells all contribute to early pregnancy loss 397 
and reproductive failure (Choudhury and Knapp 2000a, Choudhury and Knapp 2000b). Additionally, 398 
Wang et al. have previously demonstrated a positive association between early pregnancy loss and 399 
subsequent clinical pregnancy (Wang et al 2003). Although the exact reason for the dose-response 400 
relationship between miscarriage and subsequent clinical pregnancy is unknown, it can be theorised 401 
that there is some immunogenetic mechanism causing the uterus to be better prepared after an initial 402 
miscarriage so it can carry a subsequent pregnancy to term. Similar factors are likely to be important 403 
in the IVF population analysed in our study, both in terms of the pathophysiology of pregnancy loss 404 
and in the increase in live birth rate compared to those who do not achieve pregnancy. 405 
Meaning of the results/Clinical implications 406 
Our results are useful both for clinicians and for couples who have suffered a miscarriage in an initial 407 
cycle of IVF/ICSI, especially when facing the already emotionally and financially burdened decision of 408 
whether to continue treatment. Additionally, the use of the HFEA Register database, which contains 409 
information on all fertility treatments in the UK makes the results of our analysis particularly relevant 410 
for use in the UK. When communicating with couples, cumulative live birth rates are a better 411 
representation of success rates over a complete journey of IVF than traditional live birth rates and so 412 
our analysis of success rates over multiple complete cycles will aid informed decision-making and help 413 
tailor expectations for these couples.  414 
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Research Implications 415 
We propose future studies assessing the effect of timing of miscarriage on subsequent cycle 416 
outcomes, as the differing aetiologies for early and late pregnancy losses may affect future chances of 417 
live birth. There is a need for studies that are able to adjust for other confounders that we have been 418 
unable to address, such as history of previous miscarriage, BMI, smoking and ovarian reserve. 419 
Additionally, in a larger dataset the effects of other types of pregnancy loss e.g. ectopic or molar 420 
pregnancies could be assessed.  421 
Conclusion 422 
Women who have a live birth or miscarriage in their first complete cycle of IVF have a higher chance 423 
of having an IVF baby than women who do not become pregnant. This information is reassuring for 424 
couples considering their options for continuing treatment after an initial pregnancy loss.   425 
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 517 
 518 
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 520 
 521 
 522 
Table I: Cause of pregnancy loss in first complete cycle, as a proportion of the whole population. 523 
PREGNANCY LOSS (n = 10290) n (%) 
BIOCHEMICAL PREGNANCY 4826 (4.2) 
MISCARRIAGE 4495 (3.9) 
ECTOPIC PREGNANCY 514 (0.5) 
>1 LOSS OF ANY KIND 176 (0.2) 
TERMINATION 170 (0.1) 
STILLBIRTH 100 (0.1) 
MOLAR PREGNANCY 9 (0.01) 
 524 
Table II: Age and other characteristics of women entering their second cycle, by outcome of first 525 
cycle. 526 
CHARACTERISTIC OUTCOME OF FIRST CYCLE, n (%) unless otherwise stated 
 NO PREGNANCY MISCARRIAGE LIVE BIRTH 
n (%) 39413 (79.9) 5369 (10.9) 3931 (8.0) 
Age (year), mean (SD) 35 (4.4) 35 (4.2) 35 (3.9) 
 <31 6258 (15.9) 802 (14.9) 427 (15.4) 
 31-35 14555 (36.9)  1987 (37.0) 1499 (38.1) 
 36-40 14588 (37.0)  2097 (39.1) 1636 (41.6) 
 >40 4012 (10.2)  483 (9.0) 369 (9.4) 
Duration of infertility, 
median(IQR) 
5 (3-7) 4 (3-7) 6 (4-8) 
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CHARACTERISTIC OUTCOME OF FIRST CYCLE, n (%) unless otherwise stated 
 NO PREGNANCY MISCARRIAGE LIVE BIRTH 
 Missing 4277 (10.9) 515 (9.6) 355 (9.0) 
Type of infertility    
 Primary 28965 (73.5) 3665 (74.0) 2737 (78.7) 
 Secondary 10448 (26.5) 1704 (26.0) 1194 (21.3) 
Cause of infertility    
 >1 cause 5845 (14.8) 791 (14.7) 605 (15.4) 
 Tubal 6544 (16.6) 874 (16.3) 564 (14.3) 
 Anovulatory 2547 (6.5) 355 (6.6) 224 (5.7) 
 Male factor 13175 (33.4) 1858 (34.6) 1627 (41.4) 
 Endometriosis 1393 (3.5) 154 (2.9) 108 (2.7) 
 Unexplained 9737 (24.7) 1316 (24.5) 782 (19.9) 
 Missing 172 (0.4) 21 (0.4) 21 (0.5) 
 527 
 528 
Table III: Treatment information for second cycle, by outcome of first cycle. 529 
TREATMENT 
INFORMATION 
OUTCOME OF FIRST CYCLE, n (%) unless otherwise stated 
 NO PREGNANCY MISCARRIAGE LIVE BIRTH 
IVF 19768 (50.2)  2764 (51.5) 1829 (46.5) 
ICSI 19645 (49.8)  2605 (48.5) 2102 (53.5) 
Oocytes collected, 
median (IQR) 
8 (5-12) 9 (5-13) 10 (6-14) 
Stage and number of 
embryos  transferred 
   
 No transfer 4597 (11.7) 366 (6.8) 268 (6.8) 
 Single cleavage 3346 (8.5) 376 (7.0) 341 (8.7) 
 Single blastocyst 133 (0.3) 34 (0.6) 93 (2.4) 
 Double cleavage 25095 (63.7) 3757 (70.0) 2726 (69.3) 
 Double blastocyst 1067 (2.7) 244 (4.5) 222 (5.6) 
 Triple cleavage 4462 (11.3) 507 (9.4) 209 (5.3) 
 Triple blastocyst 114 (0.3) 18 (0.3) 17 (0.4) 
 Missing 599 (1.5) 67 (1.2) 55 (1.4) 
 530 
 531 
Table IV: Outcomes of second complete cycle, by outcomes of first complete cycle. 532 
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OUTCOME OF SECOND 
COMPLETE CYCLE 
OUTCOME OF FIRST COMPLETE CYCLE, n (%)  
n= 487131 
 NO PREGNANCY MISCARRIAGE LIVE BIRTH 
NO PREGNANCY 26835 (68.1) 2953 (55.0) 1942 (49.4) 
LIVE BIRTH, NO LOSS 8488 (21.5) 1571 (29.3) 1440 (36.6) 
MISCARRIAGE, NO LIVE 
BIRTH 
3260 (8.3) 650 (12.1) 404 (10.3) 
MISCARRIAGE AND LIVE 
BIRTH 
437 (1.1) 118 (2.2) 72 (1.8) 
OTHER LOSS 331 (0.8) 66 (1.2) 51 (1.3) 
LOST TO FOLLOW UP 62 (0.2) 11 (0.2) 22 (0.6) 
1Total study population (n=112549) minus women who discontinued treatment after the first 533 
complete cycle (n= 63836: no pregnancy = 30663, miscarriage = 3952, live birth = 29221). 534 
 535 
 536 
 537 
 538 
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Table V: Live birth rates by first cycle outcome 539 
 540 
 541 
COHORT (FIRST CYCLE 
OUTCOME) 
Cycle Live births N. From cohort Conditional live birth 
rate / cycle 
Conservative cumulative 
live birth rate 
Optimal cumulative 
live birth rate 
NO PREGNANCY 2 8993 39413 22.8 (22.40, 23.23) 22.8 (22.40, 23.23) 22.8 (22.39, 23.21) 
 3 2888 15503 18.6 (18.02, 19.24) 30.1 (29.69, 30.60) 38.4 (37.83, 38.97) 
 4 892 5701 15.7 (14.70, 16.59) 32.4 (31.95, 32.87) 49.7 (48.97, 50.43) 
 5 265 2073 12.8 (11.35, 14.22) 33.1 (32.62, 33.54) 57.8 (56.87, 58.73) 
 6 88 797 11.0 (8.87, 13.22) 33.3 (32.84, 33.77) 64.1 (62.92, 65.28) 
 7 30 317 9.5 (6.24, 12.69) 33.4 (32.91, 33.85) 69.0 (67.50, 70.50) 
MISCARRIAGE 2 1704 5369 31.7 (30.49, 32.98) 31.7 (30.49, 32.98) 31.7 (30.45, 32.95) 
 3 494 2123 23.3 (21.47, 25.07) 40.9 (39.62, 42.25) 49.5 (48.00, 51.00) 
 4 123 739 16.6 (13.96, 19.33) 43.2 (41.90, 44.55) 59.8 (58.04, 61.56) 
 5 40 286 14.0 (9.97, 18.01) 44.0 (42.65, 45.30) 67.1 (64.99, 69.21) 
 6 13 109 11.9 (5.84, 18.01) 
 
44.2 (42.89, 45.55) 72.4 (69.80. 75.00) 
 
LIVE BIRTH 2 1524 3931 38.8 (37.25, 40.29) 38.8 (37.25, 40.29) 38.8 (37.28, 40.32) 
 3 403 1341 30.1 (27.60, 32.51) 49.0 (47.46, 50.58) 57.9 (56.09, 59.71) 
 4 107 454 23.6 (19.66, 27.47) 51.7 (50.18, 53.30) 68.5 (66.40, 70.60) 
 5 35 166 21.1 (14.88, 27.29) 52.6 (51.07, 54.19) 75.5 (72.97, 78.03) 
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Table VI: Couple characteristics at the second complete cycle and their effect on the chance of live 542 
birth over multiple subsequent complete cycles (adjusted odds ratios from final model). 543 
 544 
 545 
 546 
 547 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
 564 
 565 
1 Female age at second complete cycle was found to have a non-linear relationship with the 566 
probability of live birth and was fitted as two linear effects. 567 
 568 
COUPLE CHARACTERISTICS ADJUSTED ODDS RATIO 
(95% CI) 
OUTCOME OF FIRST COMPLETE CYCLE   
 MISCARRIAGE (VERSUS NO PREGNANCY) 1.42 (1.34, 1.50) 
 LIVE BIRTH (VERSUS NO PREGNANCY) 2.04 (1.89, 2.20) 
FEMALE AGE (YEARS)1  
18-40 0.94 (0.94, 0.95) 
>40 0.63 (0.59, 0.66) 
DURATION OF INFERTILITY (YEARS) 0.99 (0.98, 0.99) 
YEAR OF SECOND CYCLE 1.03 (1.02, 1.04) 
TYPE OF INFERTILITY  
TUBAL (YES VERSUS NO) 0.88 (0.82, 0.94) 
MALE FACTOR (YES VERSUS NO) 1.07 (1.00, 1.14) 
UNEXPLAINED (YES VERSUS NO) 1.04 (0.97, 1.11) 
ANOVULATORY (YES VERSUS NO) 1.02 (0.96, 1.09) 
ENDOMETRIOSIS (YES VERSUS NO) 0.97 (0.90, 1.06) 
COMPLETE CYCLE NUMBER (VERSUS CYCLE 2)  
3 0.86 (0.82, 0.90) 
4 0.72 (0.67, 0.78) 
5 0.63 (0.55, 0.71) 
6 0.54 (0.43, 0.67) 
TREATMENT CHARACTERISTICS  
TREATMENT USED (IVF VERSUS ICSI) 1.11 (1.05, 1.16) 
NUMBER OF EGGS COLLECTED 1.04 (1.04, 1.04) 
STAGE OF EMBRYOS TRANSFERRED (VERSUS 
DOUBLE CLEAVAGE) 
 
NONE TRANSFERRED 0.28 (0.25, 0.31) 
SINGLE CLEAVAGE 0.49 (0.45, 0.54) 
SINGLE BLASTOCYST 1.59 (1.24, 2.05)  
DOUBLE BLASTOCYST 1.75 (1.59, 1.94) 
TRIPLE CLEAVAGE 0.98 (0.92, 1.05) 
TRIPLE BLASTOCYST 1.45 (1.04, 2.01) 
Nagelkerke R2= 0.123 
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Figure Legends 569 
Figure 1: Flow chart of exclusion criteria 570 
Figure 2: Optimal (A) and conservative (B) cumulative live birth rates per woman by outcome of first 571 
complete cycle. 572 
Figure 3: Optimal cumulative live birth rates, by age group and outcome of first complete cycle (A) 573 
miscarriage (B) live birth (C) no pregnancy.  574 
Supplementary figure 1: Continuation rates after Cycle 1, by outcome of first complete cycle. 575 
Women who had a live-birth in their first complete cycle had a much higher discontinuation rate 576 
after this first complete cycle than those who did not. 577 
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